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Abstract
The killer cell immunoglobulin-like receptors (KIRs) expressed on the surface of natural killer
(NK) cells recognize specific major histocompatibility complex class I (MHC-I) molecules and
regulate NK cell activities against pathogen-infected cells and neoplasia. In human
immunodeficiency virus (HIV) infection, survival is linked to host KIR and MHC-I genotypes. In
the simian immunodeficiency virus (SIV) macaque model, however, the role of NK cells is
unclear due to the lack of information on KIR-MHC interactions. Here, we describe the first
characterization of a KIR-MHC interaction in pig-tailed macaques (Macaca nemestrina). Initially,
we identified three distinct subsets of macaque NK cells that stained ex vivo with macaque MHC-I
tetramers loaded with SIV peptides. We then cloned cDNAs corresponding to 15 distinct KIR3D
alleles. One of these, KIR049-4, was an inhibitory KIR3DL that bound MHC-I tetramers and
prevented activation, degranulation and cytokine production by macaque NK cells after
engagement with specific MHC-I molecules on the surface of target cells. Furthermore, KIR049-4
recognized a broad range of MHC-I molecules carrying not only the Bw4 motif but also Bw6 and
non-Bw4/Bw6 motifs. This degenerate, yet peptide-dependent, MHC reactivity differs markedly
from the fine specificity of human KIRs.
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Introduction
Natural killer (NK) cells are critical components of the innate immune system that
contribute to protection against intracellular pathogens and neoplasia (1–4). The principal
determinant of NK cell activation and function is the ability to discriminate between healthy
cells and the altered signature of pathogen-infected or transformed cells. In particular, viral
infection and neoplasia frequently down-regulate the cell surface expression of major
histocompatibility complex class I (MHC-I) molecules to escape immune pressure mediated
by CD8+ T lymphocytes. These phenotypic changes can trigger NK cell activation.
NK cells recognize MHC-I molecules via a large array of germ-line encoded cell surface
receptors that provide both activating and inhibitory signals (5–7). In primates, these
receptors comprise members of the C-type lectin-like family (NKG2A-E) and a number of
Ig superfamily molecules, such as leukocyte immunoglobulin-like receptors (LILRs) and
killer cell immunoglobulin-like receptors (KIRs) (8). MHC-I molecules constitute a major
ligand for several of these receptors, including KIRs (9).
KIR molecules are encoded by several highly polymorphic genes that produce cell surface
proteins with either two (KIR2D) or three (KIR3D) extracellular Ig-like domains. In
addition, the transmembrane domain and cytoplasmic tail occur in two distinct forms. KIR
molecules with long tails (KIR2DL, KIR3DL) provide inhibitory signals due to the presence
of ITIMs (10). In contrast, KIR molecules with short tails (KIR2DS, KIR3DS) provide
activating signals mediated by the adaptor protein DAP12, which associates with a charged
residue in the KIR transmembrane domain (5).
In humans, KIRs possess fine specificity for defined groups of MHC-I molecules
characterized by specific motifs at the C-terminal end of the ͣ1 helix. KIR2DL1 recognizes
HLA-C molecules that possess asparagine and lysine at positions 77 and 80, respectively.
KIR2DL2 and KIR2DL3 recognize all the other HLA-C molecules, which harbor serine and
asparagine at positions 77 and 80, respectively. In contrast, KIR3DL1 specifically
recognizes HLA-B molecules with a Bw4 motif (NLR[I/T]ALR) between positions 77 and
83. Other HLA-B molecules, which lack the Bw4 motif, harbor the distinct Bw6 sequence
(SLRNLRG) that is not recognized by any human KIRs. The vast majority of HLA-A
molecules carry neither the Bw4 nor the Bw6 motif and are not recognized by KIRs, except
for HLA-A*03 and HLA-A*11, which bind KIR3DL2 in a peptide-dependent manner (11).
The ligands for most activating KIRs are currently unknown.
The polymorphic KIR genes have been shown to play a critical role during viral infection.
For example, genetic studies have demonstrated that the presence of KIR2DL3 in hepatitis C
virus-infected patients correlates with improved viral control (12). Similarly, specific
combinations of MHC-I (HLA alleles harboring the Bw4-80I motif) and KIR (KIR3DL1/
KIR3DS1) genes are associated with slower progression to AIDS in HIV-1-infected patients
(13, 14). Furthermore, KIR3DL1/S1+ NK cells expand in vivo during acute HIV-1 infection
in individuals carrying HLA-Bw4 alleles (15). However, the precise mechanism of
protection is still unclear and ligands for KIR3DS1 have yet to be identified. Studies in
animal models could help to elucidate the protective role of NK cells during HIV-1
infection.
Infections of Asian macaques with simian immunodeficiency viruses (SIV) or SIV/HIV
chimeras (SHIV) are classical primate models of HIV disease. Rhesus macaques (Macaca
mulatta), pig-tailed macaques (Macaca nemestrina) and cynomolgus macaques (Macaca
fascicularis) are the most commonly used species for this purpose. In these animals, SIV or
SHIV infection recapitulates the pathology and disease progression observed in HIV-1-
infected humans (16). The organization of MHC genes in these three species is markedly
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different compared to the human MHC region. Specifically, macaques lack the MHC-C
gene but possess several copies of both the MHC-A and MHC-B genes. These are called
Mamu, Mane or Mafa genes in rhesus, pig-tailed and cynomolgus macaques, respectively.
Numerous macaque MHC-I alleles have been sequenced, and immunogenic viral epitopes
presented by the expressed proteins have been identified in some cases (17–22). In addition,
certain macaque MHC-I alleles are associated with lower viral loads and protection against
SIV/SHIV disease development (23–25).
The role of NK cells during SIV/SHIV infection in macaques remains unclear. NK cell
depletion experiments have failed to demonstrate a significant impact on SIV load and
disease progression, potentially due to partial targeting of all NK cells (26). However,
numerous KIR alleles have been identified in rhesus and cynomolgus macaques (27–30),
and some studies have reported an effect of specific KIR alleles on viral load, independently
of MHC background (31, 32).
Although macaque MHC and KIR sequence diversity has been studied extensively, little is
known about macaque KIR specificity for MHC-I ligands. Only two studies have identified
specific KIR-MHC pairs in rhesus macaques (33, 34). Colantonio et al. demonstrated that
KIR3DL05 recognizes Mamu-A1*002 (34). Similarly, Rosner et al. showed that KIR3DL05
and KIR3DLw03 interact with several Mamu-A, but not with Mamu-B molecules in vitro
(33). These KIRs also interact strongly with human HLA-C molecules (35).
Here, we describe the first KIR-MHC interaction in pig-tailed macaques. The identified
receptor, named KIR049-4, is a member of the inhibitory KIR3DL family and exhibits broad
peptide-dependent reactivity against both Bw4 and non-Bw4 MHC-I molecules.
Materials and Methods
Animals and viruses
Pig-tailed macaques were maintained in accordance with the Guide for the Care and Use of
Laboratory Animals (36). Animal handling and experiments were approved by the NIAID
Institutional Animal Care and Use Committee. Macaques were housed in a biosafety level 2
facility. Biosafety level 3 practices were followed. Macaques were anesthetized with
intramuscular injections of ketamine hydrochloride (Ketaject; Phoenix Pharmaceutical Inc.,
St Joseph, MO) and acepromazine acetate (Fermenta Animal Health Co., Kansas City, MO)
during phlebotomy and virus inoculations. Ten macaques had been inoculated intravenously
several years earlier with CXCR4-tropic SHIV of low pathogenicity. At the time of study,
plasma RNA viral loads were below the limit of detection in all infected macaques and
CD4+ T lymphocyte counts were within the normal range.
KIR3D cloning and sequencing
Macaque KIR3D cDNAs were cloned as described previously (28). Briefly, 1 μg of total
RNA, extracted from macaque PBMCs using Tri-reagent (Molecular Research Center,
Cincinnati, OH), was used to synthesize cDNA using random hexamers and Superscript III
reverse transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. KIR cDNAs were amplified by PCR using KIR-S1 (5′-
CAGCACCATGTCGCTCAT-3′) sense and KIR-R1 (5′-
GGGGTCAAGTGAAGTGGAGA-3′) reverse primers with high fidelity Phusion
polymerase (New England Biolabs, Ipswich, MA). The PCR reactions were heated at 98°C
for 30 sec, then amplifications were conducted over 28 cycles of 98°C for 5 sec, 63°C for 1
sec and 72°C for 20 sec. A final extension was conducted at 72°C for 5 min. The PCR
product (~1.6 kb) was gel-purified using the Qiaquick gel extraction kit (Qiagen, Valencia,
CA) and cloned into the pCR4Blunt-TOPO vector (Invitrogen). Between 24 and 60
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individual clones were sequenced per animal using a 3130xl Genetic Analyzer (Applied
Biosystems, Foster City, CA). The sequences of the pig-tailed macaque KIR3D alleles
described in this study have been deposited in GenBank (http://www.ncbi.nlm.nih.gov/
genbank/) under accession number HQ713453-HQ713467.
Phylogenetic analysis
KIR3DL and KIR3DS sequences were aligned separately using the Cluster W program in
the MacVector 11.1.2 software suite (MacVector Inc., Cary, NC) with minor manual
adjustments. Phylogenetic trees were constructed using the neighbor-joining method.
Genetic distances were estimated using Kimura’s two-parameter method (37). Bootstrap
analysis (1,000 replicates) was performed to assign confidence values to tree nodes (38).
Cell lines
The MHC-I deficient cell line 721.221 (39), kindly provided by Dr. Eric Long (Laboratory
of Immunogenetics, NIAID, NIH), was maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin-G and 100 U/ml
streptomycin (R10 medium).
To generate target cells expressing single macaque MHC-I allele, full-length cDNAs
encoding the pig-tailed macaque MHC-I alleles Mane-A1*003:01, -A1*082:01, -
A1*084:01, -A3*13:01 and -B*109:01, were cloned into the EcoRI restriction site of
pcDNA3.1(+) (Invitrogen). Two million 721.221 cells were nucleofected with 2 μg of
plasmid DNA using the Amaxa Cell Line Nucleofector kit V (Lonza, Germany) and the
T-020 program on a Nucleofector II device (Lonza, Germany), then cultured at 37°C in R10
medium lacking antibiotics. At 20 hr post-nucleofection, cell surface expression of MHC-I
molecules was verified by flow cytometry using a PE-conjugated MHC-I-specific mAb
(clone W6/32; AbD Serotec, Raleigh, NC). Cells were cultured for one week in R10
medium supplemented with 0.70 mg/ml geneticin (Invitrogen), then positively selected for
MHC-I expression on the cell surface using PE-conjugated anti-MHC-I mAb and MACS
anti-PE microbeads (Miltenyi Biotec Inc., Auburn, CA) as specified by the manufacturer.
Stable cell lines were maintained afterwards in R10 medium supplemented with 0.70 mg/ml
geneticin (Invitrogen).
Macaque KIR3D cDNAs were modified by PCR to insert a Flag epitope (DYKDDDDK)
between the leader peptide and the D0 domain. Modified KIR3D cDNAs were cloned into
the EcoRI restriction site of pcDNA3.1(+) (Invitrogen). Plasmids encoding macaque Flag-
KIR3D constructs were nucleofected into the 721.221 cell line as described for MHC-I
alleles. At 20 hr post-nucleofection, cell surface expression of Flag-KIR3D molecules was
verified by flow cytometry using a PE-conjugated Flag-specific mAb (clone M2; Abcam,
Cambridge, MA). Cells were cultured for one week in R10 medium supplemented with 0.70
mg/ml geneticin (Invitrogen), then positively selected for Flag expression on the cell surface
using PE-conjugated anti-Flag mAb and MACS anti-PE microbeads (Miltenyi Biotec Inc.)
as described for the MHC-I cell lines. Stable cell lines were maintained afterwards in R10
medium supplemented with 0.70 mg/ml geneticin (Invitrogen).
MHC genotyping by PCR-SSP
Mane-A1*082 genotyping was performed on genomic DNA extracted from macaque
PBMCs using the Wizard Genomic DNA purification kit (Promega Corporation, Madison,
WI). Briefly, a sequence-specific amplification (PCR-SSP) was performed using Mane-
A3S2 sense (CAACACACAGACCTACCGAGAGAA) and Mane-A3R reverse
(CTCTGATCTGCTCCGCCG) primers with AmpliTaq DNA polymerase (Perkin Elmer,
Wellesley, MA). An internal control for amplification was obtained using Mane-DRBS3
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sense (GAGTGTCATTTCTTCAACGGGA) and Mane-DRBR2 reverse
(CCTCGCCGCTGCACTGT) primers. The PCR reactions were heated at 94°C for 5 min,
then amplifications were conducted over 25 cycles of 94°C for 30 sec, 65.5°C for 30 sec,
and 72°C for 30 sec. A final extension was conducted at 72°C for 7 min. PCR reactions
were loaded onto a 1.5% agarose TAE gel and separated by electrophoresis. A 246bp Mane-
DRB-specific product was amplified in all macaques, whereas a 493bp product was
generated in Mane-A1*082+ macaques. Mane-A1*082-specific amplicons were gel-purified
using the Qiaquick gel extraction kit (Qiagen) and directly sequenced using a 3130xl
Genetic Analyzer (Applied Biosystems). Mane-A4*14 genotyping was performed as
described previously (18).
Tetramer production
Fluorochrome-conjugated tetrameric peptide-MHC-I (pMHC-I) complexes were produced
as described previously (40).
Tetramer staining of macaque PBMCs
One million freshly isolated macaque PBMCs were labeled with pMHC-I tetramers
conjugated to either PE or allophycocyanin for 15 min at room temperature (RT) in the dark.
Cells were labeled further with anti-CD3 (clone SP34-FITC, clone SP34-2-PE or clone
SP34-2-allophycocyanin; BD Biosciences), anti-CD8 (clone SK1-PerCP; BD Biosciences),
anti-CD14 (clone RMO52-FITC or clone RMO52-allophycocyanin; Beckman Coulter) and
anti-CD20 (clone B9E9-FITC or clone B9E9-allophycocyanin; Beckman Coulter) mAbs for
30 min at 4°C, then washed twice with PBS and resuspended in PBS containing 1%
formaldehyde. At least 200,000 events were acquired per test using a FACSCalibur flow
cytometer (BD Biosciences). Data were analyzed with FlowJo software version 9.3.2 (Tree
Star Inc., Ashland, OR).
Tetramer staining of KIR-expressing cell lines
One million 721.221 parental cells and KIR-expressing cell lines were stained with PE-
conjugated pMHC-I tetramers for 30 min at RT in the dark. KIR surface expression was
assessed independently for each cell line by staining with a PE-conjugated Flag-specific
mAb (clone M2; Abcam) for 30 min at 4° C. Cell samples were washed twice with PBS,
resuspended in PBS and stained with 7-AAD (Via-Probe; BD Biosciences) for 10 min at RT
in the dark prior to acquisition. At least 60,000 events were acquired per test using a
FACSCalibur flow cytometer (BD Biosciences). Data were analyzed with FlowJo software
version 9.3.2 (Tree Star Inc.).
Immunophenotyping of macaque NK cells
Macaque peripheral blood samples were stained at RT with mAbs against CD3 (clone SP34-
FITC; BD Biosciences), CD8 (clone SK1-PerCP; BD Biosciences), CD14 (clone RMO52-
allophycocyanin; Beckman Coulter), CD20 (clone B9E9-allophycocyanin; Beckman
Coulter) and NK markers coupled to PE. The following mAbs were used: (i) anti-CD16
clone 3G8, anti-CD56 clone MY31, anti-CD2 clone S5.2, anti-NKG2D clone 1D11, anti-
CD158a clone anti-HP-3E4, CD158b clone CH-L, anti-CD158 clones DX27 and DX9 (BD
Biosciences); (ii) anti-NKp30 clone Z25, anti-NKp46 clone BAB281, anti-NKp80 clone
MA152, anti-NKG2A clone Z199, anti-CD161 clone HP-3G10, and anti-CD158b clone
GL183 (Beckman Coulter); (iii) anti-LILRA2 clone 135.4, anti-LILRA4 clone
eBio17G10.2, anti-LILRB1 clone HP-F1, anti-LILRB2 clone 42D1, anti-LILRB3 clone
MK5.7H5.1 and anti-LILRB4 clone ZM4.1 (eBioscience); and, (iv) anti-KIR2D clone
NKVFS1 (Miltenyi Biotec Inc). After 15 min, RBCs were lysed with FACS lysing solution
(BD Biosciences) for 10 min, then the samples were washed twice with PBS. Cells were
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resuspended in PBS containing 1% formaldehyde. At least 200,000 events were acquired per
test using a FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using
CellQuest Pro software version 6.0 (BD Biosciences).
Functional assays
To monitor NK cell activation or TNFͣ production by NK cells, freshly isolated macaque
PBMCs were incubated for 5 hr in the presence of brefeldin A (GolgiPlug; BD Biosciences),
either alone or at a NK:target ratio of 1:1 based on the percentage of NK cells in the PBMC
sample, with parental 721.221 cells or 721.221 cell lines expressing Mane-A or Mane-B
alleles. Cells were subsequently washed once with PBS, labeled with either PE-conjugated
pMHC-I tetramers for 15 min at RT or PE-conjugated anti-KIR2D mAb (clone NKVFS1;
Miltenyi Biotec Inc) for 30 min at 4°C, then stained with anti-CD3 (clone SP34-FITC; BD
Biosciences) and anti-CD8 (clone SK1-PerCP; BD Biosciences) mAbs for 30 min at 4°C.
After two further washes with PBS, the cells were permeabilized for 10 min using
Permeabilization Solution 2 (BD Biosciences), washed with PBS and stained with anti-
CD69 (clone FN50-allophycocyanin; BD Biosciences) or anti-TNFͣ (clone mAb11-
allophycocyanin; BD Biosciences) mAb for 30 min at 4°C. After two final washes with
PBS, cells were resuspended in PBS containing 1% formaldehyde.
To monitor NK cell degranulation, macaque PBMCs were incubated for 5 hr in the presence
of anti-CD107a and anti-CD107b mAbs (clone H4A3-FITC and clone H4B4-FITC; BD
Biosciences) either alone or at a NK:target ratio of 1:1, with parental 721.221 cells or
721.221 cell lines expressing Mane-A or Mane-B alleles. Monensin (GolgiStop; BD
Biosciences) was added for the last 4 hr. Cells were then washed once with PBS, labeled
with PE-conjugated pMHC-I tetramers for 15 min at RT, and stained with anti-CD3 (clone
SP34-allophycocyanin, BD Biosciences) and anti-CD8 (clone SK1-PerCP; BD Biosciences)
mAbs for 30 min at 4°C. After two further washes with PBS, cells were resuspended in PBS
containing 1% formaldehyde.
For all assays, at least 300,000 events were acquired per test using a FACSCalibur flow
cytometer (BD Biosciences). Data were analyzed with FlowJo software version 9.3.2 (Tree
Star Inc.).
Results
Macaque CD3-CD8+ lymphocyte subsets bind pMHC-I tetramers ex vivo
In the SIV/SHIV pig-tailed macaque model, CD8+ T-cell responses specific for the SIV
Gag-derived epitope KP9 (KKFGAEVVP) contribute to viral control and improved survival
in monkeys carrying the Mane-A1*084 allele (formerly known as Mane-A*10) (20). We
identified a different Gag-derived epitope (DI9: DHQAAMQII) presented by the Mane-
A1*082 allele (formerly known as Mane-A*03). Mane-A1*082+ macaques infected with
SIV/SHIV were found to harbor CD8+ T lymphocytes specific for this epitope as measured
by intracellular staining for IFNͥ and TNFͣ (data not shown). Although KP9-specific
CD8+ T-cell responses were detected in all Mane-A1*084+ SIV/SHIV-infected macaques
tested, only a fraction of infected Mane-A1*082+ macaques responded to the DI9 epitope.
To investigate whether this poor response frequency was due to the lack of peptide-specific
CD8+ T-cells, we stained PBMCs from Mane-A1*082+ SHIV-infected macaques directly
ex vivo using Mane-A1*082 tetramers loaded with the DI9 peptide or an N-terminal
truncated variant (HI8: HQAAMQII). Each tetramer detected a subset of CD8+ T-cells in
Mane-A1*082+ macaques that exhibited IFNͥ responses upon in vitro stimulation with the
DI9 peptide (Fig. 1A). We did not detect specific tetramer staining of CD8+ T-cells from
Mane-A1*082+ SHIV-infected macaques that failed to produce IFNͥ upon DI9 peptide
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stimulation, suggesting that the lack of response was due to the absence of peptide-specific
CD8+ T-cells. However, in the same samples, a significant fraction (13.9 to 24.7%) of CD3-
CD8+ cells stained with the Mane-A1*082 tetramers (Fig. 1B). Both tetramers recognized
the same CD3-CD8+ lymphocyte subset, as demonstrated by co-staining experiments using
Mane-A1*082 tetramers conjugated with different fluorochromes (Fig. 1C), suggesting that
subsets of CD3-CD8+ lymphocytes express a receptor capable of binding pMHC-I
complexes.
Tetramer-binding CD3-CD8+ lymphocyte subsets are present irrespective of MHC genetic
background or infection status
Next, we analyzed freshly isolated PBMCs from a cohort of 20 pig-tailed macaques that
included 10 Mane-A1*082+ animals (50%). Ten macaques (50%) had been infected with a
CXCR4-tropic SHIV and 10 macaques (50%) were uninfected. We identified Mane-A1*082
tetramer-binding CD3-CD8+ lymphocytes in 7 animals, but the presence of these cells was
independent of infection status or Mane-A1*082 genotype (Table I). Five macaques
harbored CD3-CD8+ lymphocytes that stained similarly with both Mane-A1*082 tetramers.
Two additional macaques possessed a subset of CD3-CD8+ cells that stained with the HI8/
Mane-A1*082 tetramer but not with the DI9/Mane-A1*082 tetramer.
To expand our observations, we used Mane-A4*14 (formerly known as Mane-A*17)
tetramers loaded with another Gag-derived peptide (AF9: ALAPVPIPF) (41). Four
macaques harbored a subset of CD3-CD8+ lymphocytes that bound the AF9/Mane-A4*14
tetramer. As with the Mane-A1*082 tetramers, the presence of a Mane-A4*14 tetramer-
binding CD3-CD8+ lymphocyte subset was independent of infection status and MHC
genotype (Table I).
The receptors responsible for binding the AF9/Mane-A4*14 and Mane-A1*082 tetramers
are clearly distinct. Moreover, co-staining experiments of CD3-CD8+ lymphocytes from one
animal (PT98P033) with both AF9/Mane-A4*14 and HI8/Mane-A1*082 tetramers revealed
distinct but overlapping subsets of cells reactive with each pMHC-I complex (Fig. 1D).
Thus, macaque CD3-CD8+ lymphocytes express receptors with diverse specificity for
pMHC-I complexes. Indeed, three distinct patterns of tetramer binding were observed, likely
resulting from the expression of three different receptors. One receptor recognizes both
Mane-A1*082 complexes, but not AF9/Mane-A4*14. A second receptor binds Mane-
A1*082 in a peptide-dependent manner. A third receptor is specific for the Mane-A4*14
molecule.
Peptide-MHC-I tetramers bind NK cell subsets directly ex vivo
The observation of pMHC-I tetramer staining within the CD3-CD8+ cell subset was
somewhat unexpected because these reagents are typically used to analyze epitope-specific
CD8+ T-cells, which express CD3 as part of the TCR complex. Thus, the absence of CD3
expression by tetramer-binding cells suggested the involvement of a different hematopoietic
lineage. We hypothesized that the tetramer-positive cells were NK cells, which do express
CD8ͣ but lack CD3 molecules.
To evaluate the role of macaque NK cells in pMHC-I tetramer binding, we performed
immunophenotyping assays on peripheral blood samples from 20 animals using a panel of
10 distinct markers (Supplementary Table I). First, CD16 and CD56, two markers used to
distinguish human NK cell subsets, were evaluated (42). A large majority of CD3-CD8+
cells expressed high levels of CD16, but only a small fraction was positive for CD56,
consistent with previous studies of rhesus macaque NK cells (43). Almost all CD3-CD8+
lymphocytes expressed CD2, an adhesion molecule expressed by both T lymphocytes and
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NK cells. Among natural cytotoxicity triggering receptors (NCR), NKp30 and NKp46 were
expressed on most CD3-CD8+ cells. In contrast, NKp44, a receptor expressed on tissue NK
cells, was not detected (mean 0.0% +/− 0.1%; data not shown). CD3-CD8+ lymphocytes
also expressed high levels of the lectin-like receptors NKp80, NKG2A and NKG2D
(Supplementary Table I). CD161 expression by CD3-CD8+ cells was more variable between
individual macaques. The expression of CD16, NKp30 and NKp46 was almost exclusively
detected on CD3-CD8+ cells and was virtually absent on CD3+CD8+ cells (Supplementary
Table I); the other markers tested were less specific for NK cells.
Next, we examined expression of 6 distinct LILR receptors (LILRA2, LILRA4, LILRB1,
LILRB2, LILRB3, LILRB4) on macaque cells. A mAb specific for LILRB3 (CD85a)
reacted with monocytes only (data not shown). The five additional human LILR-specific
mAbs did not cross-react with macaque molecules. Among 6 distinct mAbs specific for
human KIR2D (HP-3E4, GL183, CH-L, DX27, NKVFS1) and KIR3D (DX9) molecules,
only one of them (NKVFS1) was reactive with macaque cells (Supplementary Table I and
data not shown).
KIR2D was expressed on a subset of CD3-CD8+ cells that displayed variable frequencies
between macaques (mean 22.1% +/− 15.6%; range 0.3% – 68.2%). Three distinct staining
patterns were observed. Intense staining of KIR2D+ cells was observed in 7 macaques
(35%) and dimmer staining was detected in 8 additional macaques (40%) (data not shown).
Five macaques (25%) harbored both bright and dim KIR2D+ subsets within the CD3-CD8+
cell population, suggesting that NKVFS1 recognizes multiple macaque KIR2D molecules
that are either differentially expressed or bind the mAb with distinct affinities.
Collectively, these findings indicate that the CD3-CD8+ cell population comprises NK cells
rather than CD8+ T-cells with down-regulated CD3 expression (Supplementary Table I).
The high frequency of tetramer-binding cells observed in uninfected macaques further
argues against a T-cell origin. However, none of the markers tested displayed concordant
expression profiles that could explain the observed patterns of tetramer reactivity.
Cloning of KIR3D alleles from pig-tailed macaques
To identify the receptors responsible for pMHC-I tetramer binding, we investigated the
distribution of tetramer-binding cells among CD16+ and KIR2D+ NK cells. The Mane-
A1*082 and Mane-A4*14 tetramer-binding cells were found mainly among CD16+ NK
cells, which are known to preferentially express KIR molecules in humans (44) (Fig. 2A).
However, tetramer staining did not co-segregate with KIR2D expression (Fig. 2B). These
results led us to consider KIR3D molecules.
On this basis, we cloned KIR3D alleles from 4 pig-tailed macaques, including one animal
(PT93P049) with NK cells that bound both Mane-A1*082 tetramers and one animal
(PT98P033) with NK cells that bound both the HI8/Mane-A1*082 and AF9/Mane-A4*14
tetramers. We identified 9 KIR3DL and 6 KIR3DS alleles in this small group of macaques,
with each animal expressing multiple activating and inhibitory receptors. All KIR3DL
molecules possessed long cytoplasmic tails containing two ITIMs (Fig. 3). In contrast, the
KIR3DS molecules had very short cytoplasmic tails and their transmembrane domains
harbored an arginine residue that was absent from the KIR3DL molecules. (Fig. 3)
Next, we compared pig-tailed macaque KIR3DL and KIR3DS allele sequences by
phylogenetic analysis to alleles previously identified from rhesus and cynomolgus
macaques. Pig-tailed macaque KIR3DL sequences intermingled with alleles from the two
other macaque species to form five distinct clusters containing representatives from each
macaque species (Fig. 4). This observation suggests the presence of five conserved KIR3DL
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loci among pig-tailed, rhesus and cynomolgus macaques. Similar phylogenetic comparisons
performed with KIR3DS alleles demonstrated that the sequence diversity of pig-tailed
macaque KIR3DS alleles was comparable to that of KIR3DS alleles found in rhesus and
cynomolgus macaques. However, there was no evidence for the conservation of activating
KIR loci among macaque species, as no clustering of KIR3DS alleles was observed (data
not shown).
The KIR3DL molecule KIR049-4 recognizes Mane-A1*082
To identify KIR3D alleles encoding pMHC-I tetramer-binding receptors, we expressed 4
KIR3DS and 4 KIR3DL cDNAs, the latter from distinct allelic clusters, in 721.221 cells.
Due to the lack of available mAbs specific for macaque KIR3D molecules, we inserted a
Flag epitope between the leader peptide and the first extracellular Ig-like domain (D0), and
established stable cell lines expressing high levels of each KIR3D molecule on the cell
surface (Fig. 5A, top row). Whereas the KIR3DL alleles were expressed at high levels and
remained stable, expression of the KIR3DS alleles was somewhat lower and generally less
stable.
Each cell line was tested for its ability to bind Mane-A1*082 and Mane-A4*14 tetramers.
None of the KIR3D cell lines bound the AF9/Mane-A4*14 tetramer above background
levels observed with parental 721.221 cells (Fig. 5B). Cells expressing KIR049-4, however,
bound both Mane-A1*082 tetramers (Fig. 5A, bottom row; Fig. 5B). Consistent with these
findings, the KIR049-4 allele was cloned from a macaque (PT93P049) with NK cells
reactive against both Mane-A1*082 tetramers (Fig. 1B). In contrast, none of the other 7
KIR3D cell lines bound either of the Mane-A1*082 tetramers. The KIR049-4 cell line also
bound weakly to the KP9/Mane-A1*084 tetramer (Fig. 5B).
KIR049-4 interactions with Mane-A1*082 and Mane-A1*084 molecules inhibit NK cell
responses
The KIR049-4 allele encodes a KIR3DL molecule, which should generate inhibitory signals
upon cognate ligand engagement. To formally address this, we monitored the responses of
primary macaque NK cells after in vitro stimulation with the MHC-deficient cell line
721.221, or 721.221 variants expressing single macaque MHC-A or MHC-B alleles (Mane-
A1*082, -A1*084, -A1*003, -A3*13, -B*109). After stimulation, NK cells were analyzed
for induced expression of CD69, a marker of cellular activation. NK cells expressing
KIR049-4 or other Mane-A1*082 tetramer-binding receptors were identified by staining
with Mane-A1*082 tetramers and activation status was assessed for both the tetramer-
binding and non-binding subsets (Fig. 6A and Supplementary Figure 1A). In the absence of
target cells, both NK subsets exhibited low activation levels. Stimulation with 721.221 cells
or cells expressing Mane-A1*003, -A3*13 or -B*109 triggered high activation levels in both
NK subsets. In contrast, activation of KIR049-4+ or other Mane-A1*082 tetramer-binding
NK cells was almost completely inhibited after stimulation with 721.221 cells expressing
Mane-A1*082 or Mane-A1*084. Moreover, tetramer negative NK cells in the same samples
maintained high levels of CD69 expression, similar to those observed after stimulation with
other MHC alleles (Fig. 6A and Supplementary Figure 1A). Additional analyses showed that
KIR2D+ cells were not inhibited under the same conditions (Fig. 6B and Supplementary
Figure 1A). Thus, the inhibition of NK cell activation by Mane-A1*082 or Mane-A1*084
mediated was restricted to the KIR049-4+ subset.
In further experiments, the specific inhibition of NK cell activation by Mane-A1*082 and
Mane-A1*084 was associated with reduced degranulation, as monitored by surface
mobilization of CD107, and decreased TNFͣ production (Fig. 6 and Supplementary Figure
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1B–C). Collectively, these results demonstrate that KIR049-4 or related Mane-A1*082
tetramer-binding molecules are inhibitory KIRs that recognize specific MHC-I molecules.
KIR049-4 specificity is defined by the α1 helix of MHC-I molecules
To characterize KIR049-4 specificity for MHC-I binding, the five MHC-I alleles tested were
divided in two groups based on their capacity to interact with KIR049-4. Accordingly,
Mane-A1*082 and Mane-A1*084 were classified as binders, whereas Mane-A1*003, -
A3*13 and -B*109 were classified as non-binders. The protein sequences of all alleles were
analyzed for polymorphic sites that co-segregated with the ability to bind KIR049-4. Fifty-
six amino acid positions differed between the five alleles, but most of these were specific to
one allele (32 positions; 57.1%). Furthermore, the amino acids present at 17 additional
positions (30.3%) in the binder group were also found among the non-binder MHC-I alleles.
The seven remaining positions mapped to the MHC-I ͣ1 and ͣ2 helices at positions 67, 74,
76, 77, 114, 156 and 165 (Fig. 7). Five of these positions (67, 74, 77, 114, 156) contribute to
peptide-binding pockets and may affect KIR-MHC-I interactions by altering peptide
selection. The mutation at position 165 from leucine, which is found in binder MHC-I
alleles, to the valine residue present in the non-binder MHC-I alleles is unlikely to affect
KIR binding due to the similar physicochemical properties of these amino acids. In contrast,
the glutamic acid present at position 76 in the binder MHC-I alleles is replaced by either a
valine or an alanine in the non-binder MHC-I alleles. The exchange between a charged
residue and a small hydrophobic amino acid at a position exposed on the surface of the ͣ1
helix could affect the KIR3D-MHC-I interaction (Fig. 7).
KIR049-4 interacts with both the Bw4 and Bw6 motifs of MHC-I
Human KIR3DL1 recognizes MHC-I molecules bearing the Bw4 motif at the C-terminal
end of the ͣ1 helix, whereas KIR3DL2 specificity is limited to HLA-A*03 and HLA-A*11
in a peptide-dependent manner (45). Surprisingly, both macaque MHC-I molecules
recognized by KIR049-4, Mane-A1*082 and -A1*084, possess the Bw6 motif, rather than
the Bw4 motif.
To assess KIR049-4 specificity with regards to Bw4/Bw6 motifs, we stained the KIR049-4
cell line with multiple human tetramers comprising HLA molecules with Bw4, Bw6 and
non-Bw4/Bw6 motifs (Table II). KIR049-4 bound 3 distinct Bw4+ HLA molecules (HLA-
B*27:05, -B*51:01 and -B*57:01) with high avidity, but failed to bind another Bw4+ HLA
molecule (HLA-B*44:02). These interactions were specific for KIR049-4 as 4 additional
KIR3DL molecules failed to bind the same tetramers (Table II). Furthermore, the interaction
was confirmed using primary macaque NK cells expressing KIR049-4 (data not shown).
Next, we tested 3 HLA-B molecules bearing Bw6 motifs and 2 HLA-A molecules without
either the Bw4 or the Bw6 motif (Table II). KIR049-4 bound to HLA-B*07:02 and HLA-
A*03:02 tetramers in a peptide-dependent manner, albeit with lower avidities compared to
the Bw4+ tetramers. No binding was detected with HLA-A*02:01, -B*08:01 and -B*35:01
tetramers loaded with different peptides. Thus, KIR049-4 can recognize MHC-I molecules
bearing both Bw4 and Bw6 motifs in peptide-dependent manner.
Discussion
In this study, we characterized the function of a pig-tailed macaque KIR3DL molecule that
recognizes a broad range of MHC-I ligands in a peptide-dependent manner. Engagement of
this receptor by its cognate ligands inhibits NK cell activation, degranulation and cytokine
production. Although the inhibitory properties of KIR049-4 are typical of a KIR3DL
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molecule, its degenerate MHC-I recognition profile contrasts with the focused recognition
properties of human KIR molecules.
In humans, the three KIR3DL genes (KIR3DL1, KIR3DL2 and KIR3DL3) encode
polymorphic receptors with distinct MHC-I specificities (45). KIR3DL1 binds to MHC-I
molecules carrying the Bw4 motif at the C-terminal end of the ͣ1 helix, particularly those
possessing an isoleucine at position 80 (Bw4-80I) (46), whereas KIR3DL2 recognizes only
HLA-A*03 and HLA-A*11 in a peptide-dependent manner (11). The ligands for KIR3DL3
are currently unknown. Similarly, KIR2D family members recognize HLA-C molecules
based on the presence of motifs, called C1 and C2, in the same region of the MHC-I ͣ1
helix as the Bw4 motif (45). There are no known human KIRs specific for MHC-I molecules
carrying the Bw6 motif, which represent almost 50% of all HLA-B allotypes (46). In
contrast, the macaque KIR3DL molecule identified here recognizes Bw4+ MHC-I molecules
with high avidity, some Bw6+ MHC-I molecules with lower avidity and some non-Bw4/
Bw6 MHC-I molecules. In each case, the nature of the peptide presented by MHC-I affects
the strength of the interaction, with a more profound impact on the lower avidity
interactions. Despite the relatively low binding avidity for macaque Bw6+ MHC-I
molecules detected by pMHC-I staining, the interaction is sufficient to block NK cell
activation in functional assays.
Although peptides have been shown to impact human KIR-HLA interactions (47–50),
particularly in the case of KIR3DL2 molecules (11), this is often considered secondary to
the role of the presenting MHC-I heavy chain because few KIR residues interact directly
with the peptide (51–53). The degenerate MHC-I recognition characteristics of KIR049-4
suggest that macaque KIR3D molecules rely on somewhat different criteria than human
KIR3DLs for MHC-I recognition, with the bound peptide perhaps playing a more influential
role. A consequence of this peptide selectivity is that some permissive MHC-I molecules are
unable to interact with KIR049-4 in the presence of antagonist peptides, potentially due to
steric interference from peptide amino acid side chains. This is likely exemplified in our
dataset by the differential binding observed for HLA-B*07:02 tetramers bearing distinct
peptides derived from HIV and CMV (Table II). Similarly, it is possible that some MHC-I
molecules identified as non-binder in our assays, such as HLA-A*02:01, -B*08:01 and -
B*35:01, could be recognized by KIR049-4 if different, agonist peptides were loaded in the
binding groove. Accordingly, the range MHC-I molecules that can bind KIR049-4 is likely
larger than currently described. However, not all MHC-I molecules are able to bind
KIR049-4 as demonstrated in our functional assays with cell lines expressing Mane-
A1*003, -A3*13 and -B*109 (Fig. 6). In these assays, the MHC-I molecules are loaded with
numerous variable peptides derived from the intracellular compartment and likely comprise
both agonist and antagonist peptides. The lack of recognition by KIR049-4 indicates that
motifs within the MHC-I protein itself, stabilize the KIR and pMHC complex.
To gain a deeper understanding at the atomic level, we analyzed the degenerate MHC-I
recognition properties of KIR049-4 based on the structure of human KIR3DL1 complexed
with a Bw4+ MHC-I molecules (HLA-B*57:01) (53). The binding site between these two
proteins is defined by 17 amino acids in the MHC-I molecule that contact 21 amino acids in
the KIR3DL1 molecule. Most of the contact residues (11/17) in HLA-B*57:01 are shared
with macaque MHC-I molecules that bind KIR049-4. The 6 residues that differ map to
positions 19, 76, 80, 83, 142 and 151. The contact residues identified in human KIR3DL1
are equally divided between 11 amino acids (positions 9, 11, 13, 29, 34, 200, 201, 228, 230,
276 and 277) that are conserved in KIR049-4 and 10 amino acids (positions 138, 140, 165,
166, 167, 199, 227, 272, 279 and 282) that differ in KIR049-4. The pattern of conservation/
polymorphism between the human KIR3DL1 and KIR049-4 molecules suggests that the
interactions mediated by the D0 and D2 domains of KIR3D with the side of the MHC-I
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molecule and the ͣ2 helix, respectively, are conserved. Studies using KIR3DL1 mutants
have shown that the D0 domain helps to stabilize the interaction mediated by D1 and D2
over the MHC-I groove (54). Additional studies have shown that KIR2DL1 recognition can
be expanded beyond the confines of HLA-C molecules by fusion with the D0 domain of
KIR3DL1 to include some HLA-B and HLA-G molecules (55). As the contact points
present in the D0 domain of KIR3DL1 are conserved in KIR049-4, it is likely that the D0
domain of KIR049-4 is an important contributor to degenerate MHC-I recognition via
stabilization of the KIR-MHC complex.
The majority of the variable residues affect the D1 and D2 domain interactions with the ͣ1
helix, particularly around position 76 and the Bw4/Bw6 motifs region. In particular, the D1
region at positions 165–167, which contacts both the peptide and the MHC-I molecule
around position 76 and 80, differs completely between KIR049-4 and human KIR3DL1.
These clustered polymorphisms likely contribute to the degenerate MHC-I recognition
profile of KIR049-4 and its associated peptide dependency.
The ability of KIR049-4 to recognize Bw6+ MHC-I molecules is not unique. Rhesus
macaque NK cells also express specific KIR3DLs encoded by Mamu-KIR3DL05 alleles that
recognize Bw6+ MHC-I molecules in a peptide dependent manner (33, 34). Two such
KIR3DL molecules, KIR3DLw03*004 and KIR3DL05*007, display degenerate MHC-I
recognition properties and are sensitive to amino acids changes at position 77, 80 and 83
within the Bw4/Bw6 motif (33). Furthermore, polymorphic residues located in the D1
domain encoded by these KIR3DL05 alleles contribute to the peptide-dependent recognition
of Mamu-A1*002 tetramers, which carry the Bw6+ motif (34). Our analysis extends these
findings beyond the rhesus macaque model.
The characteristics of KIR049-4 described in our study have implications for other macaque
species. Indeed, phylogenetic analysis identified several KIR alleles from rhesus and
cynomolgus macaques that are highly similar to KIR049-4 (Fig. 4). In particular, the
cynomolgus macaque KIR3DL allele KIR55 differs from KIR049-4 by only one
synonymous and six non-synonymous mutations affecting the D0 domain, the D2 domain
and the cytoplasmic tail (28). As none of these mutations affect the predicted points of
contact with MHC-I molecules, KIR55 likely exhibits a degenerate MHC-I recognition
profile, similar to that of KIR049-4. Additional KIR molecules encoded by the same locus,
such as KIR07 in cynomolgus (28) and KIR3DLw03*004 in rhesus (29) macaques, possess
many additional polymorphic sites. However, these mutations map mainly outside of the
predicted points of contact, these KIR alleles likely behave similarly to KIR049-4.
Therefore, the degenerate MHC-I recognition profile observed with KIR049-4 is likely
common to the three macaque species for which we have KIR data due to conservation of
the encoding locus.
Two additional macaque NK cell receptors are apparent from the macaque pMHC-I tetramer
reactivity patterns observed in our study. These are likely KIR molecules that remain to be
identified. Based on the MHC-I binding properties of KIR molecules, it would be expected
that pMHC-I tetramer staining could be used more generally to characterize NK cells ex
vivo. However, only one previous report has described such results in rhesus macaques (34).
Multiple studies have reported staining of human NK cell clones or KIR transfectants with
pMHC-I tetramers. Indeed, this approach has allowed the characterization of specific ligands
for KIR3DL1 and KIR3DL2 (11, 48, 50, 56). In contrast, no other report has shown pMHC-
I tetramer staining of human NK cells isolated directly from blood or tissue. The reasons for
this lack of staining remain to be reconciled with our knowledge of KIR binding to MHC-I
molecules.
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Finally, the ability to characterize of NK cells using pMHC-I tetramers provides us with a
new approach that enables the study of these cells during SIV/SHIV infection. This is an
important advance because relatively few reagents are currently available to monitor the
diverse array of KIR molecules expressed in macaques.
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Figure 1. Peptide-MHC class I tetramers bind macaque CD3-CD8+ lymphocytes ex vivo
(A) Detection of virus-specific CD8+ T-cells with Mane-A1*082 tetramers in a SHIV-
infected, Mane-A1*082+ macaque (PT1246A). (B) Two Mane-A1*082 tetramers bind
subsets of CD3-CD8+ lymphocytes in a SHIV-infected, Mane-A*082+ macaque
(PT93P049) lacking CD8+ T-cells responses to the corresponding peptide epitopes.
Lymphocytes are gated as CD3-CD8+ after exclusion of CD20+ and CD14+ cells. (C) Co-
staining of CD3-CD8+ lymphocytes with HI8/Mane-A1*082 and DI9/Mane-A1*082
tetramers (PT1670). (D) Co-staining of CD3-CD8+ lymphocytes with HI8/Mane-A1*082
and AF9/Mane-A4*14 (PT98P033).
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Figure 2. Peptide-MHC-I class I tetramers staining of CD16+ and KIR2D+ NK cell subsets
(A) Patterns of pMHC-I tetramer staining as a function of CD16 expression. (B) Patterns of
pMHC-I tetramer staining as a function of KIR2D expression. In each case, representative
stainings from two macaques (PT1670, top and middle panels; PT98P033 bottom panel) are
shown. Cells are gated as CD3-CD8+ lymphocytes.
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Figure 3. Predicted protein sequences of the transmembrane and cytoplasmic domains of pig-
tailed macaque KIR3D alleles
The predicted sequences of the transmembrane domain and cytoplasmic tails of 9 KIR3DL
and 6 KIR3DS molecules from pig-tailed macaques are aligned with the corresponding
domains of human KIR3DL1*001 and KIR3DS1*010 alleles. Amino acids identical to
residues present in KIR3DL1*001 are indicated by a period (.). Gaps introduced for the
alignment are represented by dashes (−). The two conserved YxxL sequences forming the
ITIM motif in the tail of human and macaque KIR3DL alleles are boxed. Boxes in the
transmembrane domains of human and macaque KIR3DS molecules indicate basic residues
(lysine or arginine) required for KIR association with adaptor molecules such as DAP12.
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Figure 4. Phylogenetic analysis of pig-tailed macaque KIR3DL alleles
Phylogenetic analysis of KIR3DL alleles from pig-tailed (PT, red), rhesus (RH, blue) and
cynomolgus (CY, green) macaques was performed using Kimura’s two-parameter method.
The tree is rooted on one allele of both the human KIR3DL1 and KIR3DL2 loci. Bootstrap
values for 1,000 replicates are provided on the node.
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Figure 5. KIR049-4 binds Mane-A1*082 tetramers
(A) KIR expression and DI9/Mane-A1*082 tetramer staining are shown for the indicated
stable cell lines expressing macaque Flag-KIR3D molecules. Surface KIR expression was
assessed by staining with PE-conjugated anti-Flag mAb (top row, white histograms).
Staining with DI9/Mane-A1*082 tetramer is showed for the same cell lines (bottom row,
white histograms). Parental 721.221 cells stained under the same conditions are depicted in
gray. (B) Eight stable cell lines expressing distinct KIR3Ds were stained with the following
pMHC-I tetramers: HI8/Mane-A1*082, DI9/Mane-A1*082, KP9/Mane-A1*084 and AF9/
Mane-A4*14. The relative binding index, defined as the mean fluorescence intensity (MFI)
of tetramer binding to the KIR cell line divided by the MFI of tetramer binding to the
parental 721.221 cell line stained in parallel under identical conditions, is shown in each
case. Data shown represent the mean of up to 9 experiments (*** P<0.0001 by one-way
ANOVA).
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Figure 6. KIR049-4 inhibits NK cell functions in a specific MHC-I-dependent manner
(A) Activation of NK cells (left) was monitored by induction of CD69 expression after
stimulation with 721.221 cells or 721.221 variants expressing Mane-A or Mane-B alleles.
NK cells stimulated under identical conditions were also monitored for degranulation by
surface CD107a/b staining (middle) and for the production of intracellular TNFͣ (right).
Co-expression of KIR049-4 or related molecules was determined by HI8/Mane-A1*082
tetramer staining stimulation. NK cells are gated as CD3-CD8+ lymphocytes. Data shown
represent the mean of 5 independent experiments, each performed using a sample obtained
from a distinct macaque (PT1670, PT93P049, PT97P027, PT98P021, PT98P056) ***
P<0.0001; ** P<0.001 by one-way ANOVA. (B) Activation (left), degranulation (middle)
and TNFͣ production (right) among KIR2D+ and KIR2D- NK cell subsets after stimulation
with individual MHC-I molecules. These data include tetramer-positive cells present in both
the KIR2D+ and KIR2D- NK cell subsets (Fig. 2). Data shown represent the mean of 4
independent experiments, each performed using a sample obtained from a distinct macaque
(PT1670, PT93P049, PT97P027, PT98P021). PT98P056 was not included because less than
2% of the NK cells were KIR2D+ in this animal. Error bars indicate standard deviation.
Representative raw data are shown in Supplementary Figure 1.
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Figure 7. Map of polymorphic sites that distinguish binder from non-binder MHC-I molecules
The seven polymorphic residues that differ between binder and non-binder macaque MHC-I
molecules are represented in red on the HLA-B*57:01-KIR3DL1 structure (PDB: 3VH8).
The MHC-I heavy chain is shown in green and ͤ2-microglobulin is depicted in blue. The
D0, D1 and D2 domains of KIR3DL1 are shown in pink, yellow and orange, respectively.
Amino acids 165–167 in the D1 domain (red) are in close proximity to the side chain of
residue 76 in the MHC-I molecule.
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Table I
The presence of tetramer-binding NK cell subsets is independent of MHC-I genotype and infection status.
Macaque
Infection Status
Tetramer staining (NK %)
MHC Genotype A1*082
DI9
A1*082
HI8
A4*14
AF9
A1*082 A4*14
PT1670 Yes Yes No 15.9 17.5 1.4
PT93P049 Yes Yes No 10.7 20.2 0.7
PT98P021 No Yes No 17.4 22.3 1.6
PT98P056 Yes No No 13.4 14.9 4.8
PT97P027 No No No 18.7 24.0 1.3
PT99P004 No Yes No 1.1 8.5 3.4
PT98P033 Yes No No 1.1 9.0 12.5
PT96P067 No Yes No 0.8 0.9 21.4
PT98P050 Yes No Yes 0.4 0.5 8.0
PT93549 Yes No Yes 0.1 0.5 7.9
PT1246A Yes Yes No 0.7 2.6 0.7
PT98P031 No Yes No 0.4 0.6 1.3
PT99P003 No Yes No 1.4 1.6 1.9
PT210A Yes Yes Yes 0.3 0.7 0.9
PT99P015 No Yes Yes 0.6 1.1 0.5
PT93518 Yes No Yes 3.1 3.2 3.1
PT96P062 No No Yes 0.1 0.1 3.8
PT98P049 No No Yes 0.1 0.4 0.4
PTA0P045 No No Yes 0.3 0.4 0.6
PT1669 Yes No No 2.9 4.4 1.4
CD14-CD20-CD3-CD8+ lymphocytes were assessed for HI8/Mane-A1*082, DI9/Mane-A1*082 and AF9/Mane-A4*14 tetramer staining. Data represent the mean value of up to 5 independent experiments.
Values in bold represent tetramer-binding NK cell subsets.
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Table II
KIR049-4 interacts with both the Bw4 and Bw6 motifs of MHC-I in a peptide-dependent manner.
HLA Peptide Origin/Sequence KIR033-2a KIR033-7KIR049-4 KIR049-6 KIR049-7
Bw4-80I
B*51:01 HIV Env YPPPIQGVI 1.3b 2.0 69.1 1.0 0.7
B*57:01 HIV Gag ISPRTLNAW 1.2 1.8 79.0 1.2 0.9
HIV Gag TSTLQEQIGW 1.2 1.7 71.6 1.2 0.9
HIV Gag KAFSPEVIPMF 1.2 1.7 56.1 1.2 0.9
Bw4-80T
B*27:05 HIV Gag KRWIILGLNK 1.3 1.8 203.2 1.1 0.7
B*44:02 HIV RT EELRQHLLRW 1.3 2.1 1.1 1.2 1.0
Bw6
B*07:02 HIV Nef RPMTYKAAL 1.5 2.1 22.0 1.2 0.8
CMV pp65 TPRVTGGGAM 1.2 1.9 6.2 1.0 0.7
CMV pp65 RPHERNGFTV 1.4 1.9 2.4 1.0 0.7
HIV Gag GPGHKARVL 1.3 2.4 1.6 1.2 0.8
B*08:01 HIV Gag GEIYKRWII 1.2 1.1 1.1 1.1 1.2
EBV EBNA3A QAKWRLQTL 1.4 1.6 1.4 1.2 0.9
B*35:01 HIV Vif DAKLVITTY 0.9 1.1 1.6 1.0 0.8
Non-Bw4/Bw6
A*02:01 EBV BMLF1 GLCTLVAML 0.9 1.4 1.0 0.8 1.2
HIV Gag SLYNTVATL 1.1 1.6 0.9 1.0 1.2
A*03:01 HIV Env TVYYGVPVWK 1.0 1.5 4.8 1.0 0.7
HIV Gag RLRPGGKKK 1.4 1.6 0.9 0.9 0.8
a721.221 and stable cell lines expressing five different KIR3DL alleles (KIR033-2, 033-7, 049-4, 049-6 and 049-7) from distinct clusters (Fig. 4) were stained with MHC-I tetramers and analyzed by flow
cytometry.
b
Relative binding index, defined as the mean fluorescence intensity (MFI) of tetramer binding to the KIR cell line divided by the MFI of tetramer binding to the parental 721.221 cell line stained in parallel
under identical conditions.
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